The use of nolasiban, a novel oxytocin receptor antagonist, prior to embryo transfer: does it help?

Ernest Loumaye, MD, PhD

19th World Congress of Gynecological Endocrinology (On Line Congress 2-5 December 2020, available until 15 April 2021)

Abstract on p. 39 – part of SYMP19: Recent development in IVF

Gynecological and Reproductive Endocrinology and Metabolism 2020; Supplement 1 – Book of abstracts

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue